Business Wire

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

Share

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II Variation Application for trastuzumab deruxtecan, a HER2 directed antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN), for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen.

Validation confirms that the application is complete and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). This application is based on the positive results from the DESTINY-Gastric01 pivotal phase 2 trial published in The New England Journal of Medicine and the DESTINY-Gastric02phase 2 trial recently presented at the 2021 European Society for Medical Oncology (ESMO) Congress.

“After progression on initial therapy, patients with HER2 positive advanced gastric cancer are faced with limited options in Europe, so there is a significant unmet need for new therapeutic options,” said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo. “We look forward to working with the EMA on its review of this application and to potentially bring trastuzumab deruxtecan to physicians and patients in Europe, as it offers the potential to provide an important new treatment option to patients with locally advanced or metastatic HER2 positive gastric or GEJ adenocarcinoma who have received a prior anti-HER2-based regimen.”

About HER2 Positive Gastric Cancer

Gastric (stomach) cancer is the fifth most common cancer worldwide and the fourth highest leading cause of cancer mortality, with a five-year global survival rate of 5% to 10% for advanced or metastatic disease.1,2,3 There were approximately one million new cases of gastric cancer and 768,000 deaths reported worldwide in 2020.4 In Europe, approximately 136,000 cases of gastric cancer are diagnosed annually, and Eastern Europe has the second highest incidence of gastric cancer worldwide after Eastern Asia.3,4 Gastric cancer is the sixth leading cause of cancer death in Europe, and is typically diagnosed in the advanced stage but even when diagnosed in earlier stages of the disease the survival rate remains modest.3,5,6,7

Approximately one in five gastric cancers are HER2 positive.8,9 HER2 is a tyrosine kinase receptor growth promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancers.9 HER2 overexpression may be associated with a specific HER2 gene alteration known as HER2 amplification.9

Recommended first-line treatment for HER2 positive advanced or metastatic gastric cancer is combination chemotherapy plus trastuzumab, an anti-HER2 medicine, which has been shown to improve survival outcomes when added to chemotherapy.10 For patients with metastatic gastric cancer that progress following initial treatment with a trastuzumab-based regimen, treatment options are limited, and in many regions in the world there are no additional HER2 directed medicines available.1,5,11

About DESTINY-Gastric01

DESTINY-Gastric01 is a pivotal, randomized, open-label, multi-center phase 2 trial assessing the safety and efficacy of trastuzumab deruxtecan (6.4 mg/kg) in patients from Japan and South Korea with HER2 positive (defined as IHC3+ or IHC2+/ISH+) advanced gastric cancer or gastroesophageal junction adenocarcinoma who have progressed on two or more prior treatment regimens including fluoropyrimidine (5-FU), platinum chemotherapy and trastuzumab. Patients were randomized 2:1 to receive trastuzumab deruxtecan or physician’s choice of chemotherapy (paclitaxel or irinotecan monotherapy). The primary endpoint of DESTINY-Gastric01 is objective response rate (ORR). Secondary endpoints include overall survival (OS), progression-free survival (PFS), duration of response (DoR), disease control rate and time to treatment failure as well as pharmacokinetic and safety endpoints. DESTINY-Gastric01 enrolled 189 patients at multiple sites in Japan and South Korea. For more information about the trial, visit ClinicalTrials.gov.

About DESTINY-Gastric02

DESTINY-Gastric02 is an open-label, single-arm, phase 2 trial in Western patients evaluating the safety and efficacy of trastuzumab deruxtecan (6.4 mg/kg) in patients with HER2 positive metastatic and/or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen. The primary endpoint of DESTINY-Gastric02 is confirmed ORR based on independent central review. Secondary endpoints include PFS, OS, DoR and safety. DESTINY-Gastric02 enrolled 79 patients at multiple sites in North America and Europe. For more information about the trial, visit ClinicalTrials.gov.

About Trastuzumab Deruxtecan

Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Trastuzumab deruxtecan consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

Trastuzumab deruxtecan (5.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens based on the results from the DESTINY-Breast01 trial.

Trastuzumab deruxtecan (6.4 mg/kg) is approved in Israel, Japan, Singapore, and U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

About the Trastuzumab Deruxtecan Clinical Development Program

A comprehensive global development program is underway evaluating the efficacy and safety of trastuzumab deruxtecan monotherapy across multiple HER2 targetable cancers including breast, gastric, lung and colorectal cancers. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

Trastuzumab deruxtecan was highlighted in the Clinical Cancer Advances 2021report as one of two significant advancements in the “ASCO Clinical Advance of the Year: Molecular Profiling Driving Progress in GI Cancers,” based on data from both the DESTINY-Gastric01 and DESTINY-CRC01trials, as well as one of the targeted therapy advances of the year in non-small cell lung cancer (NSCLC) based on the interim results of the HER2 mutated cohort of the DESTINY-Lung01 trial.

Trastuzumab deruxtecan recently received its fourth Breakthrough Therapy Designation (BTD) in the U.S., which was for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens.

About the Daiichi Sankyo and AstraZeneca Collaboration

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize trastuzumab deruxtecan in March 2019and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of trastuzumab deruxtecan and datopotamab deruxtecan.

About Daiichi Sankyo in Oncology

The oncology portfolio of Daiichi Sankyo is powered by our team of world-class scientists that push beyond traditional thinking to create transformative medicines for people with cancer. Anchored by our DXd antibody drug conjugate (ADC) technology, our research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in the U.S. We also work alongside leading academic and business collaborators to further advance the understanding of cancer as Daiichi Sankyo builds towards our ambitious goal of becoming a global leader in oncology by 2025.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

___________________________________

References

1 Casamayor M, et al. Ecancermedicalscience. 2018;12:883.

2 SEER Survival rates: Stomach 2004-2017. Accessed: October 2021.

3 Sung H, et al. Ca Cancer J Clin. 2021;71:209–249.

4 WHO. International Agency of Cancer Research. Cancer Today. Accessed October 2021.

5 Thuss-Patience PC, et al. Lancet Oncol. 2017;18(5):640-653.

6 Cancer Research UK. Stomach Cancer Survival Statistics. Accessed October 2021.

7 SEER Cancer Stat Facts: Stomach Cancer. Accessed October 2021.

8 Iqbal N, et al. Mol Biol Int. 2014;2014:852748.

9 Abrahao-Machado LF, et al. World J Gastroenterol. 2016;22(19):4619-4625.

10 Oditura M, et al. World J Gastroenterol. 2014 Feb 21;20(7):1635-49.

11 Satoh T, et al. J Clin Oncol. 2014;32(19):2039‐2049.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

Global:
Victoria Amari
Daiichi Sankyo, Inc.
vamari@dsi.com
+1 908 900 3010 (mobile)

EU:
Lydia Worms
Daiichi Sankyo Europe GmbH
lydia.worms@daiichi-sankyo.eu
+49 (89) 7808751 (office)
+49 176 11780861 (mobile)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations:
DaiichiSankyoIR@daiichisankyo.co.jp

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure2.12.2021 22:01:00 CET | Press release

Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the winners of the 2021 Going Digital Awards in Infrastructure. The annual awards program recognizes the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005219/en/ Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure (Photo: Business Wire) Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. To see the Going Digital Awards in Infrastructure finalists present their projects, click here. Bentley Systems showcased 19 Going Digital Awards in Infrastructure winners on December 2 during the 2021 Year in Infrastructure and Going Digital Awards

Vifor Pharma comments on market speculations2.12.2021 18:40:00 CET | Press release

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions. Vifor Pharma is therefore regularly in discussions with other market participants and does not comment on them. About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core b

Covid - 19: Laboratoire Cerba Detects First Case of Omicron Variant in Mainland France2.12.2021 16:44:00 CET | Press release

Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport. The authorities - Santé Publique France [Public Health France], Agence Régionale de Santé Ile de France [Paris Regional Health Agency] and Direction Générale de Santé [General Directorate for Health]- were immediately informed. Laboratoire Cerba, chosen last October by the French Health Authorities to participate in the Emergen consortium, carries out between 1,000 and 1,500 sequencings per week with results returned in less than 5 days. Sylvie Cado, CEO of Laboratoire Cerba explains: "From the beginning of the epidemic, we have been working closely with the Authorities and the National Reference Centres to share the information and the strains of interest in order to support our Authorities in steering public policy: the systematic

i2c Partners with BEYON Money and Visa to Launch First Open Banking Super App in Bahrain2.12.2021 16:23:00 CET | Press release

i2c Inc., a leading provider of digital payment and banking technology, today announced its partnership with BEYON Money, the mobile super app launched by Batelco Financial Services, which is the fintech arm of Bahrain’s leading digital solutions and telecommunications provider. Backed by a recently-secured, first-of-its-kind open banking license from the Central Bank of Bahrain, the BEYON Money super app will host a digital wallet that enables retail, bill, and peer-to-peer payments for its users, connects to bank accounts through open banking, delivers financial insights and provides digital remittances. BEYON Money will develop card issuing and processing functionalities through i2c’s agile banking and payments platform which will also integrate additional partners and services. Through i2c’s Fintech Fast Track certification, BEYON Money will tap into Visa’s network infrastructure to launch a digital-first debit program to the market with a physical card option available upon reques

ENTERPRISE AND MEDIA ORGANIZATIONS DRIVE REVENUE, ENGAGEMENT, AND DEMAND WITH BRIGHTCOVE SOLUTIONS, INDEPENDENT STUDY REVEALS2.12.2021 15:00:00 CET | Press release

Brightcove Inc. (Nasdaq: BCOV), the global leader in video for business, released findings that enterprises and media organizations can generate 225% and 226% ROI respectively with Brightcove and see a full return on the initial investment in less than six months. The commissioned Total Economic Impact™ (TEI) studies conducted by Forrester Consulting examined cost savings and business benefits with Brightcove solutions for enterprise and media organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005560/en/ Forrester Consulting interviewed decision-makers at multiple enterprise and media organizations with experience using Brightcove. Respondents came from organizations headquartered in the US and EMEA, all with multi-billion dollars of annual revenues. The enterprise interviewees represented industries including automotive manufacturing, technology manufacturing, and media services that primarily use video to

ElectReon Brings Wireless Inductive Electric Vehicle Charging Technology to Italy’s “Arena of the Future”2.12.2021 14:00:00 CET | Press release

ElectReon (TASE: ELWS.TA), the leading provider of inductive in-road charging technology for commercial and passenger electric vehicles, announced the launch of the “Arena of the Future'' project in Brescia, Italy where the company has integrated its wireless technology to charge an IVECO bus and Stellantis’s Fiat Nuova 500 passenger vehicle while driving. This project is demonstrating contactless charging for a range of EVs as they drive on highways and toll roads as a potential pathway to decarbonizing long-haul transportation systems along motorway transport corridors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005493/en/ ElectReon announces the launch of "Arena of the Future" in Italy (Photo: Business Wire) The construction and technical implementation of the 1,050-metre-long circuit equipped with ElectReon’s properarity in-road charging coils and supported by 1MW of electrical power has been successfully compl

Orbital Insight Integrates with Esri's ArcGIS Platform to Streamline Satellite and Sensor Imagery Analysis2.12.2021 14:00:00 CET | Press release

Orbital Insight's fusion of multisensor geospatial data and state-of-the-art algorithms has been helping customers address critical concerns for years—from determining the flow of container ship traffic amid unprecedented supply chain delays to visualizing dynamic intelligence and defense-related threats and anomalies across the globe. With the adoption of Esri's ArcGIS Platform, Orbital Insight is making it easier for its users to integrate with ArcGIS and analyze their data. Customers of Esri, the world leader in location intelligence, who also use Orbital Insight GO can now seamlessly work between both systems, making it easier to meet spatial challenges with Esri basemap visualizations directly within the Orbital Insight GO platform and export their analysis to ArcGIS. The integration with Esri's ArcGIS Platform provides an integral reference point for analysts as well as a more cohesive and natural user experience. More collaboration is planned, including eventually incorporating